Appendix A to NDA Regulatory Filing Review

NOTE: The term "original application" or "original NDA" as used in this appendix denotes the NDA submitted. It does not refer to the reference drug product or "reference listed drug."

An original application is likely to be a 505(b)(2) application if:

(1) it relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application,
(2) it relies for approval on the Agency's previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval, or
(3) it relies on what is "generally known" or "scientifically accepted" about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean any reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations); OTC monograph deviations(see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

(1) The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies),
(2) No additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness for the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application, and,
(3) All other “criteria” are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

(1) Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the
original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2),

(2) The applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement, or

(3) The applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your ODE’s Office of Regulatory Policy representative.
Appendix B to NDA Regulatory Filing Review
Questions for 505(b)(2) Applications

1. Does the application reference a listed drug (approved drug)?
   YES ☒ NO ☐
   If "No," skip to question 3.

2. Name of listed drug(s) referenced by the applicant (if any) and NDA/ANDA #(#s): NDA 50-756, Benzaclin (1% clindamycin, 5% benzoyl peroxide)

3. Is this application for a drug that is an "old" antibiotic (as described in the draft guidance implementing the 1997 FDAMA provisions? (Certain antibiotics are not entitled to Hatch-Waxman patent listing and exclusivity benefits.)
   YES ☒ NO ☐
   If "Yes," skip to question 7.

4. Is this application for a recombinant or biologically-derived product?
   YES ☐ NO ☐
   If "Yes, contact your ODE's Office of Regulatory Policy representative.

5. The purpose of the questions below (questions 5 to 6) is to determine if there is an approved drug product that is equivalent or very similar to the product proposed for approval that should be referenced as a listed drug in the pending application.

   (a) Is there a pharmaceutical equivalent(s) to the product proposed in the 505(b)(2) application that is already approved?
       YES ☐ NO ☐
       Pharmaceutical equivalents are drug products in identical dosage forms that: (1) contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified release dosage forms that require a reservoir or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; (2) do not necessarily contain the same inactive ingredients; and (3) meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates. (21 CFR 320.1(c))

   If "No, to (a) skip to question 6. Otherwise, answer part (b and c)).

   (b) Is the pharmaceutical equivalent approved for the same indication for which the 505(b)(2) application is seeking approval?
       YES ☐ NO ☐

   (c) Is the approved pharmaceutical equivalent(s) cited as the listed drug(s)?
       YES ☐ NO ☐

   If "Yes," (c), list the pharmaceutical equivalent(s) and proceed to question 6.

   If "No," to (c) list the pharmaceutical equivalent and contact your ODE's Office of Regulatory Policy representative.

   Pharmaceutical equivalent(s):

   Version 6/14/2006
6. (a) Is there a pharmaceutical alternative(s) already approved? YES □ NO □

(Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form or as the same salt or ester. Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times and/or dissolution rates. (21 CFR 320.1(d)) Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.)

If "No," to (a) skip to question 7. Otherwise, answer part (b and (c)).

(b) Is the pharmaceutical alternative approved for the same indication for which the 505(b)(2) application is seeking approval? YES □ NO □

(c) Is the approved pharmaceutical alternative(s) cited as the listed drug(s)? YES □ NO □

If "Yes," to (c), proceed to question 7.

NOTE: If there is more than one pharmaceutical alternative approved, consult your ODE's Office of Regulatory Policy representative to determine if the appropriate pharmaceutical alternatives are referenced.

If "No," to (c), list the pharmaceutical alternative(s) and contact your ODE's Office of Regulatory Policy representative. Proceed to question 7.

Pharmaceutical alternative(s):

7. (a) Does the application rely on published literature necessary to support the proposed approval of the drug product (i.e. is the published literature necessary for the approval)? YES □ NO □

If "No," skip to question 8. Otherwise, answer part (b).

(b) Does any of the published literature cited reference a specific (e.g. brand name) product? Note that if yes, the applicant will be required to submit patent certification for the product, see question 12. No.

8. Describe the change from the listed drug(s) provided for in this (b)(2) application (for example, "This application provides for a new indication, otitis media" or "This application provides for a change in dosage form, from capsules to solution").

9. Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA? (Normally, FDA may refuse-to-file such NDAs (see 21 CFR 314.101(d)(9)). YES □ NO □

10. Is the application for a duplicate of a listed drug whose only difference is that the extent to which the active ingredient(s) is absorbed or otherwise made available to the site of action less than that of the reference listed drug (RLD)? (See 314.54(b)(1)). If yes, the application may be refused for filing under 21 CFR 314.101(d)(9)). YES □ NO □
11. Is the application for a duplicate of a listed drug whose only difference is that the rate at which the product's active ingredient(s) is absorbed or made available to the site of action is unintentionally less than that of the RLD (see 21 CFR 314.54(b)(2))? If yes, the application may be refused for filing under 21 CFR 314.101(d)(9).

   YES ☐    NO ☒

12. Are there certifications for each of the patents listed in the Orange Book for the listed drug(s) referenced by the applicant (see question #2)?
   (This is different from the patent declaration submitted on form FDA 3542 and 3542a.) See #3 Above ("old" antibiotic)

   YES ☐    NO ☒

13. Which of the following patent certifications does the application contain? (Check all that apply and identify the patents to which each type of certification was made, as appropriate.)

   ☒ Not applicable (e.g., solely based on published literature. See question #7
    See #3 Above ("old" antibiotic)

   ☐ 21 CFR 314.50(i)(1)(i)(A)(1): The patent information has not been submitted to FDA.
    (Paragraph I certification)
    Patent number(s):

   ☐ 21 CFR 314.50(i)(1)(i)(A)(2): The patent has expired. (Paragraph II certification)
    Patent number(s):

   ☐ 21 CFR 314.50(i)(1)(i)(A)(3): The date on which the patent will expire. (Paragraph III certification)
    Patent number(s):

   ☐ 21 CFR 314.50(i)(1)(i)(A)(4): The patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the application is submitted. (Paragraph IV certification)
    Patent number(s):

   NOTE: IF FILED, and if the applicant made a "Paragraph IV" certification [21 CFR 314.50(i)(1)(i)(A)(4)], the applicant must subsequently submit a signed certification stating that the NDA holder and patent owner(s) were notified the NDA was filed [21 CFR 314.52(b)]. The applicant must also submit documentation showing that the NDA holder and patent owner(s) received the notification [21 CFR 314.52(e)]. OND will contact you to verify that this documentation was received.

   ☐ 21 CFR 314.50(i)(3): Statement that applicant has a licensing agreement with the patent owner (must also submit certification under 21 CFR 314.50(i)(1)(i)(A)(4) above).
    Patent number(s):

   ☐ Written statement from patent owner that it consents to an immediate effective date upon approval of the application.
    Patent number(s):


   ☐ 21 CFR 314.50(i)(1)(iii): The patent on the listed drug is a method of use patent and the labeling for the drug product for which the applicant is seeking approval does not include any indications that are covered by the use patent as described in the corresponding use code in the
Orange Book. Applicant must provide a statement that the method of use patent does not claim any of the proposed indications. (Section viii statement)

Patent number(s):

14. Did the applicant:

- Identify which parts of the application rely on the finding of safety and effectiveness for a listed drug or published literature describing a listed drug or both? For example, pharm/tox section of application relies on finding of preclinical safety for a listed drug.

  If “Yes,” what is the listed drug product(s) Benzaclin and which sections of the 505(b)(2) application rely on the finding of safety and effectiveness or on published literature about that listed drug Module 2.6.2, Nonclinical Pharmacology

  Was this listed drug product(s) referenced by the applicant? (see question # 2)

  YES ☑ NO ☐

- Submit a bioavailability/bioequivalence (BA/BE) study comparing the proposed product to the listed drug(s)?

  N/A ☐ YES ☐ NO ☑

The BE study compared another of the sponsor’s proposed products (under review in ANDA # 065443) —— (1% clindamycin, 5% benzoyl peroxide) to Benzaclin

15. (a) Is there unexpired exclusivity on this listed drug (for example, 5 year, 3 year, orphan or pediatric exclusivity)? Note: this information is available in the Orange Book.

  YES ☐ NO ☑

The RLD is an “old” antibiotic

If “Yes,” please list:

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Product No.</th>
<th>Exclusivity Code</th>
<th>Exclusivity Expiration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version 6/14/2006
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Tamika White
3/13/2008 10:02:42 AM
CSO

Maria Walsh
3/14/2008 03:16:13 PM
CSO
Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology

Date: September 16, 2008

To: Susan Walker, M.D., Director
Division of Dermatology and Dental Products

Through: Jodi Duckhorn, M.A., Team Leader
Patient Labeling and Education Team
Division of Risk Management (DRISK)

From: Sharon R. Mills, BSN, RN, CCRP
Patient Product Information Specialist
Patient Labeling and Education Team
Division of Risk Management (DRISK)

Subject: Review of Patient Labeling (Patient Package Insert)

Drug Name(s): Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% )

Application Type/Number: NDA 50-819

Applicant/sponsor: Dow Pharmaceutical Sciences, Inc.

OSE RCM #: 2008-430
1 INTRODUCTION

Dow Pharmaceutical Sciences, Inc. submitted an original New Drug Application, NDA 50-819, for Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%). The Division of Medication Error and Prevention Analysis (DMEPA) recommended against use of this proposed Proprietary Name in their review dated June 3, 2008. It is our understanding that the Proprietary Name, Acanya Gel, has been found to be acceptable. Acanya Gel is indicated for the topical treatment of acne vulgaris in people 12 years of age and older. The sponsor’s original labeling includes a Professional Information which includes a Patient Package Insert with Patient Instructions for Use.

The reviewing division requested that the Patient Labeling and Education Team review the patient labeling submitted by the sponsor. This review is written in response to that request.

2 MATERIAL REVIEWED

- DRAFT ACANYA Gel Professional Information (PI) submitted by the sponsor on December 21, 2007 and further revised by the review division on September 8, 2008.
- DRAFT ACANYA Gel Patient Package Insert (PPI) submitted by the sponsor on December 21, 2007 and further revised by the review division on September 8, 2008.
- Section 13.6 and Appendix 2 of the Clinical Study Protocol, Protocol No.: DPSI-06-22-2006-012, submitted on December 21, 2007 as part of the NDA submission.

3 DISCUSSION

The purpose of patient information leaflets is to facilitate and enhance appropriate use and provide important risk information about medications. Our recommended changes are consistent with current research to improve risk communication to a broad audience, including those with lower literacy.

The draft PPI submitted by the sponsor has a Flesch Kinkaid grade level of 7.6, and a Flesch Reading Ease score of 62.0. To enhance patient comprehension, materials should be written at a 6th to 8th grade reading level, and have a reading ease score of at least 60% (60% corresponds to an 8th grade reading level). The reading scores as submitted by the sponsor are acceptable. However, our PPI revisions have improved the readability scores to a Flesch Kinkaid grade level of 6.6 and a Flesch Reading Ease score of 69.4%.

In our review of the PPI, we have:
- simplified wording and clarified concepts where possible,
- made the PPI consistent with the PI,
- rearranged information due to conversion of the PI to PLR format,
- removed unnecessary or redundant information
- Although not required for Patient Information, we have put this PPI in the question-and-answer format specified in the Medication Guide Regulations (21 CFR 208.20) that we recommend for all FDA approved patient labeling.
- ensured that the PPI meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006).

In 2008, The American Society of Consultant Pharmacists Foundation in collaboration with The American Foundation for the Blind published Guidelines for Prescription Labeling and
Consumer Medication Information for People with Vision Loss. They recommend using fonts such as Arial, Verdana, or APHont to make medical information more accessible for patients with low vision. We have reformatted the PPI document using the font APHont, which was developed by the American Printing House for the Blind specifically for low vision readers.

See the attached document for our recommended revisions to the PPI. Comments to the review division are **bolded, underlined and italicized**.

We are providing the review division a marked-up and clean copy of the revised PPI. We recommend using the clean copy as the working document.

All future relevant changes to the PI should also be reflected in the PPI.

4 CONCLUSIONS AND RECOMMENDATIONS

1. The sponsor should clarify whether they intend to include the PPI in the packaging with prescriptions of ACANYA Gel as well as with the premixed sample jars of ACANYA Gel. It is important for all patients to read and follow the Instructions for applying ACANYA Gel.

2. In the section “Who should not use ACANYA Gel?” the 3rd bullet lists colitis and diarrhea with past antibiotic use. Diarrhea occurs with many antibiotics. The distinction should be made that the sponsor is talking about severe diarrhea. Define severe diarrhea for patients as this is subjective.

3. In the section “How should I use ACANYA Gel,” we have added language referring patients to see the section “Patients may receive the premixed sample jar of ACANYA Gel from their doctor. There are slightly different instructions related to the expiration dates for the premixed sample jar and the prescription formulation that the pharmacist mixes.

4. In the Instructions for applying ACANYA Gel: The dosing protocol included in the original NDA submission says to use an amount of gel that is the size of a - pea; however, in the PPI, the sponsor - . Patients may not be clear about what is the size if a - pea. It is unclear whether the intention of the proposed PPI language is to apply a - pea-sized amount of gel to each of the 6 areas (1 - pea vs. 6 - peas. We have revised the language to be consistent with the method used in the dosing protocol. The proposed instruction here is also inconsistent with the 4th bullet in PI section 17.1 Instructions for Use. Telling patients to apply the gel to the “affected areas” may convey the idea that they should rub the gel into pimplles, as opposed to spreading a thin layer of the gel evenly over the whole face after applying the dots, except for the eyes and lips. The protocol specifically says that patients should not be instructed to treat only specific lesions. We recommend revising the Instructions for applying ACANYA Gel accordingly. Sections 17.1 (Instructions for Use) and 17.5 (Patient Labeling) should be consistent. The sponsor should add a labeled figure that is to-scale to show patients the size of a - pea. The figure should be referenced in the text.

5. In the section “What are the possible side effects of ACANYA Gel?” we recommend removing the language about “sun exposure”. “Sun exposure” is not an adverse reaction. The information regarding sun exposure appears to be based on animal data for this product. Unless the sponsor can tell the patient what the adverse reaction is and why they need to avoid sun exposure we do not think this information belongs in the PPI. For some
other products that contain clindamycin and benzoyl peroxide, there may be clinical experience that demonstrates possible sunburn; therefore, in those cases it may be appropriate to include language about sun sensitivity in PPIs for those products.

If “sun exposure” language is retained in the PPI, the Table of Contents in the PI should be updated to include the new section 17.4 (Sun Exposure).

Please let us know if you have any questions.
9 Page(s) Withheld

___ Trade Secret / Confidential (b4)

✓ Draft Labeling (b4)

___ Draft Labeling (b5)

___ Deliberative Process (b5)

Withheld Track Number: Other Reviews-
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Sharon Mills
9/16/2008 09:17:29 AM
DRUG SAFETY OFFICE REVIEWER

Jodi Duckhorn
9/16/2008 10:30:22 AM
DRUG SAFETY OFFICE REVIEWER